Skip to main content
. 2026 Aug 26;19(9):1348. doi: 10.3390/ph19091348
ESCC esophageal squamous cell carcinoma
G/GEJ gastric/gastroesophageal junction
HCC hepatocellular carcinoma
PDAC pancreatic ductal adenocarcinoma
DCR disease control rate
PD progressive disease
TRAEs treatment-related adverse events
irAEs immune-related adverse events
OS overall survival
PFS progression-free survival
CI confidence interval